Abstract 435P
Background
The association between hypnotic drugs and risk of cancer remains controversial. Therefore, we performed a meta-analysis to investigate this association.
Methods
Pubmed and Embase were searched systematically were searched to identify publications up to May 2020. The Newcastle-Ottawa scale for observational studies was used to assess the quality of studies. All included studies were evaluated by two reviewers independently; any discrepancies were resolved through discussion.
Results
A total of 28 observational epidemiological studies including 22 case-control studies and 6 cohort studies with 340,614 hypnotics users and 1,828,057 non-users were included in the final analyses. Hypnotics (benzodiazepines and Z-drugs) use was significantly associated with an increased risk of cancer (odds ratio [OR] or relative risk [RR] 1.17; 95% confidence interval 1.09–1.26) in a random-effects meta-analysis of all studies. Subgroup meta-analyses by various factors such as study design, type of case-control study, study region, and methodological quality of study showed consistent findings. Also, a significant dose-response relationship was observed between the use of hypnotics and the risk of cancer.
Conclusions
This meta-analysis revealed association between use of hypnotics drugs and risk of cancer. However, a high heterogeneity was observed among identified studies and results were inconsistent in some subgroups. Randomized control trials are needed to confirm the results in future.
Clinical trial identification
Editorial acknowledgement
This study was supported by grants from the Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation (TCRD-TPE-109-18).
Legal entity responsible for the study
The author.
Funding
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session
286P - Improved diagnostic accuracy on MR imaging in post-surgical recurrent head and neck SCC lesions using decision tree classification system
Presenter: Ankush Jajodia
Session: e-Poster Display Session
287P - Establishment of nasopharyngeal carcinoma organoid culture system and preliminary exploration of drug sensitivity test in vitro
Presenter: Wang Wen
Session: e-Poster Display Session
288P - Application of volumetric modulated arc therapy (VMAT) in head and neck cancers: 5-year single institutional experience
Presenter: Hiep Doan
Session: e-Poster Display Session
289P - Radiotherapy in advanced nasopharyngeal carcinoma
Presenter: Chih Kiang Tan
Session: e-Poster Display Session
292P - Shared decision-making at the cancer institute adult outpatient clinics of a tertiary hospital in the Philippines: A cross sectional study
Presenter: Marvin Jonne Mendoza
Session: e-Poster Display Session
293P - Prolonged release (PR) oxycodone/naloxone (OXN) for cancer pain (CP) & its impact on bowel function, safety & quality of life (QoL): Systematic review
Presenter: Sam Hjelmeland Ahmedzai
Session: e-Poster Display Session
294P - Interventional pain treatment in patients with pain syndrome in advanced tumours of small pelvis
Presenter: Yakhyo Ziyaev
Session: e-Poster Display Session
295P - Assessment of the impact of palliative care on the quality of life in advanced non-small cell lung cancer patients
Presenter: Sabin Katpattil
Session: e-Poster Display Session
296P - Outcomes of repeat transhepatic percutaneous biliary drainage in patients presenting with recurrent malignant biliary stricture
Presenter: Deevia Hanji
Session: e-Poster Display Session